Brickell Biotech, Inc.

États‑Unis d’Amérique

 
Quantité totale PI 5
Rang # Quantité totale PI 308 763
Note d'activité PI 1,1/5.0    3
Rang # Activité PI 339 622
Symbole boursier BBI (nasdaq)
ISIN US10802T1051
Capitalisation 6.800M  (USD)
Industrie Biotechnology
Secteur Healthcare

Brevets

Marques

0 0
2 0
3 0
0
 
Dernier brevet 2020 - Crystalline form of sofpironium ...
Premier brevet 2009 - N,n-disubstituted aminoalkylbiph...

Derniers inventions, produits et services

2020 Invention Crystalline form of sofpironium bromide and preparation method thereof. A cocrystal containing th...
2019 Invention Applicator and system for pharmaceutical preparation and method of use. An applicator and applica...
2017 Invention Process for the synthesis of (2e, 4e, 6z, 8e)-8-(3,4-dihydronaphthalen-1(2h)-ylidene)-3,7-dimethy...
Invention Process for the synthesis of (2e,4e,6z,8e)-8-(3,4-dihydronaphthalen-1(2h)-ylidene)-3,7-dimethyloc...
2014 Invention Dp2 antagonist and uses thereof. 2-mediated diseases or conditions.
2011 Invention N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors. 2-mediated condit...
Invention 2 receptors. 2-mediated conditions or diseases.
2010 Invention Dp2 antagonist and uses thereof. Described herein is the DP2 antagonist [2'-(3-benzyl-1-ethyl-ure...
2009 Invention Antagonists of prostaglandin d2 receptors. 2-mediated conditions or diseases.
Invention Phenoxyphenyl sulfide, sulfinyl and sulfonyl antagonists of prostaglandin d2 receptors. Described...
Invention N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors. Described herein ...